Sharma Isha, Dutta Rajesh K, Singh Neel K, Kanwar Yashpal S
Department of Pathology, Northwestern University, Chicago, Illinois.
Department of Pathology, Northwestern University, Chicago, Illinois; Department of Medicine, Northwestern University, Chicago, Illinois.
Am J Pathol. 2017 Apr;187(4):724-739. doi: 10.1016/j.ajpath.2016.12.011. Epub 2017 Feb 14.
The catabolic enzyme myo-inositol oxygenase (MIOX) is expressed in proximal tubules and up-regulated in the diabetic state. Previously, we reported its transcriptional and translation regulation by high glucose (HG), osmolytes, and fatty acids. However, its epigenetic regulation is unknown. Bisulfite sequencing revealed that both human and mouse MIOX promoters, enriched with CpG sites, are hypomethylated and unmethylated under HG ambience and hyperglycemic states associated with increased MIOX expression. Eletrophoretic mobility shift assays revealed increased binding of unmethylated oligos with nucleoproteins of cells maintained under HG. In addition, a strong binding of specificity protein (Sp)-1 transcription factor with MIOX promoter was observed under HG, especially with unmethylated Sp-1 oligo. Specificity of binding was established by supershift assays and treatment with the Sp-1 inhibitor mithramycin. Promoter analysis revealed an increase in luciferase activity under HG, which was reduced after mutation of the Sp-1-binding site. Sp1 siRNA treatment reduced mRNA and protein expression of Sp-1 and MIOX and generation of reactive oxygen species derived from NADPH oxidase (NOX)-4 and mitochondrial sources. In addition, there was reduced expression of hypoxia-inducible factor-1α relevant in the pathogenesis of diabetic nephropathy. Sp1 siRNA treatment reduced fibronectin expression, an extracellular matrix protein that is increased in diabetic nephropathy and tubulopathy. HG-induced MIOX expression was also reduced with the treatment of apelin-13, which deacetylates histones. Overall, these findings highlight the epigenetic regulation of MIOX in the pathogenesis of diabetic tubulopathy.
分解代谢酶肌醇加氧酶(MIOX)在近端小管中表达,且在糖尿病状态下上调。此前,我们报道了其受高糖(HG)、渗透压溶质和脂肪酸的转录及翻译调控。然而,其表观遗传调控尚不清楚。亚硫酸氢盐测序显示,富含CpG位点的人和小鼠MIOX启动子在HG环境及与MIOX表达增加相关的高血糖状态下均处于低甲基化和未甲基化状态。电泳迁移率变动分析显示,未甲基化的寡核苷酸与在HG条件下培养的细胞的核蛋白的结合增加。此外,在HG条件下观察到特异性蛋白(Sp)-1转录因子与MIOX启动子有强烈结合,尤其是与未甲基化的Sp-1寡核苷酸。通过超迁移分析和用Sp-1抑制剂放线菌素D处理确定了结合的特异性。启动子分析显示,在HG条件下荧光素酶活性增加,而Sp-1结合位点突变后荧光素酶活性降低。Sp1小干扰RNA(siRNA)处理降低了Sp-1和MIOX的mRNA及蛋白表达以及源自烟酰胺腺嘌呤二核苷酸磷酸(NADPH)氧化酶(NOX)-4和线粒体来源的活性氧的生成。此外,糖尿病肾病发病机制中相关的缺氧诱导因子-1α的表达也降低。Sp1 siRNA处理降低了纤连蛋白的表达,纤连蛋白是一种细胞外基质蛋白,在糖尿病肾病和肾小管病变中表达增加。用可使组蛋白去乙酰化的apelin-13处理也降低了HG诱导的MIOX表达。总体而言,这些发现突出了MIOX在糖尿病肾小管病变发病机制中的表观遗传调控。